Theralase Technologies Inc. (CVE:TLT – Get Free Report) shares traded up 3.8% on Tuesday . The company traded as high as C$0.27 and last traded at C$0.27. Approximately 43,002 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 232,504 shares. The stock had previously closed at C$0.26.
Theralase Technologies Stock Up 3.7%
The firm has a market cap of C$82.79 million, a price-to-earnings ratio of -20.00 and a beta of -0.57. The firm has a fifty day simple moving average of C$0.25 and a 200-day simple moving average of C$0.27. The company has a debt-to-equity ratio of 22.13, a quick ratio of 3.40 and a current ratio of 1.37.
Theralase Technologies Company Profile
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Featured Stories
- Five stocks we like better than Theralase Technologies
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
